Skip to main content

CORRECTION article

Front. Oncol., 07 December 2023
Sec. Cancer Molecular Targets and Therapeutics
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1334938

Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

This article is a correction to:

  1. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

    1. Read original article
Yezhe Cheng&#x;Yezhe Cheng†Xiaoxi Yuan&#x;Xiaoxi Yuan†Qiang Tian&#x;Qiang Tian†Xiuying Huang&#x;Xiuying Huang†Yang Chen&#x;Yang Chen†Yuzhi PuYuzhi PuHu LongHu LongMingyu XuMingyu XuYafei JiYafei JiJia XieJia XieYuping TanYuping TanXi Zhao*Xi Zhao*Hongmei Song*Hongmei Song*
  • Center of Translational Medicine, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China

A Corrigendum on
Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

by Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, Tan Y, Zhao X and Song H (2022) Front. Oncol. 12:951589. doi: 10.3389/fonc.2022.951589

Error in Table

In the published article, there was an error in Table 5 as published.

The corrected Table 5 and its caption “Payload KL610023 pharmacokinetic parameters in plasma after administrated in cynomolgus monkey (n=4, half male and half female)” appears below.

TABLE 5
www.frontiersin.org

Table 5 Payload KL610023 pharmacokinetic parameters in plasma after administrated in cynomolgus monkey (n=4, half male and half female).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: antibody drug conjugate, SKB264, TROP2, PK-PD, solid tumor

Citation: Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y, Long H, Xu M, Ji Y, Xie J, Tan Y, Zhao X and Song H (2023) Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol. 13:1334938. doi: 10.3389/fonc.2023.1334938

Received: 08 November 2023; Accepted: 15 November 2023;
Published: 07 December 2023.

Edited and Reviewed by:

Tristan M. Sissung, National Institutes of Health (NIH), United States

Copyright © 2023 Cheng, Yuan, Tian, Huang, Chen, Pu, Long, Xu, Ji, Xie, Tan, Zhao and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hongmei Song, songhongmei@kelun.com; Xi Zhao, zhaoxi@kelun.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.